UK markets closed
  • NIKKEI 225

    -7.77 (-0.03%)

    -409.53 (-1.57%)

    -2.22 (-2.62%)

    +4.40 (+0.25%)
  • DOW

    -189.89 (-0.53%)

    -2,872.28 (-6.31%)
  • CMC Crypto 200

    -68.06 (-4.62%)
  • ^IXIC

    +38.73 (+0.25%)
  • ^FTAS

    -11.13 (-0.27%)

Insights on the Botulinum Toxins Global Market to 2026 - Featuring AbbVie, Galderma and Ipsen Among Others

·7-min read

Dublin, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The "Botulinum Toxins Market Research Report by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Botulinum Toxins Market size was estimated at USD 3,230.60 Million in 2020 and expected to reach USD 3,713.68 Million in 2021, at a Compound Annual Growth Rate (CAGR) 15.29% to reach USD 7,587.03 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Botulinum Toxins to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Application, the Botulinum Toxins Market was studied across Aesthetic and Therapeutic.

  • Based on Type, the Botulinum Toxins Market was studied across AbobotulinumtoxinA, IncobotulinumtoxinA, OnabotulinumtoxinA, and RimabotulinumtoxinB.

  • Based on Region, the Botulinum Toxins Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Botulinum Toxins Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Botulinum Toxins Market, including AbbVie Inc., Ajinomoto Bio-Pharma Services, Bausch Health Companies Inc., Daewoong Pharmaceuticals Co.Ltd., Eisai Co., Ltd, Galderma S.A., Gufic Biosciences Ltd., Hugel, Inc, Hugh Source International Ltd., Ipsen group, JUVAPLUS, Lanzhou Institute of Biological Products Co. Ltd., List Biological Labs, Inc, Medytox Inc., Merz GmbH & Co. KGaA, Object Pharma, Inc., Pfizer Inc., Revance Therapeutics, Inc., Shanghai Haohai Biological Technology Co., Ltd., and US Worldmeds, LLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Botulinum Toxins Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Botulinum Toxins Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Botulinum Toxins Market?
4. What is the competitive strategic window for opportunities in the Global Botulinum Toxins Market?
5. What are the technology trends and regulatory frameworks in the Global Botulinum Toxins Market?
6. What is the market share of the leading vendors in the Global Botulinum Toxins Market?
7. What modes and strategic moves are considered suitable for entering the Global Botulinum Toxins Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers Rising number of non-invasive cosmetic procedures Increasing individuals highly conscious of their appearance Rising aging population demand for procedures to make their skin look young
5.1.2. Restraints Relatively high cost of the procedure
5.1.3. Opportunities Increasing number of product approvals and launch of novel products Surging awareness of therapeutic and cosmetic application of botulinum toxin
5.1.4. Challenges Probable side effects of the procedure
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Botulinum Toxins Market, by Application
6.1. Introduction
6.2. Aesthetic
6.3. Therapeutic

7. Botulinum Toxins Market, by Type
7.1. Introduction
7.2. AbobotulinumtoxinA
7.3. IncobotulinumtoxinA
7.4. OnabotulinumtoxinA
7.5. RimabotulinumtoxinB

8. Americas Botulinum Toxins Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Botulinum Toxins Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Botulinum Toxins Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. AbbVie Inc.
12.2. Ajinomoto Bio-Pharma Services
12.3. Bausch Health Companies Inc.
12.4. Daewoong Pharmaceuticals Co.Ltd.
12.5. Eisai Co., Ltd
12.6. Galderma S.A.
12.7. Gufic Biosciences Ltd.
12.8. Hugel, Inc
12.9. Hugh Source International Ltd.
12.10. Ipsen group
12.12. Lanzhou Institute of Biological Products Co. Ltd.
12.13. List Biological Labs, Inc
12.14. Medytox Inc.
12.15. Merz GmbH & Co. KGaA
12.16. Object Pharma, Inc.
12.17. Pfizer Inc.
12.18. Revance Therapeutics, Inc.
12.19. Shanghai Haohai Biological Technology Co., Ltd.
12.20. US Worldmeds, LLC

13. Appendix

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting